AngioDynamics (NASDAQ:ANGO) Reaches New 1-Year High – Here’s What Happened

AngioDynamics, Inc. (NASDAQ:ANGO) reached a new 52-week high on Monday . The company traded as high as $15.41 and last traded at $15.3060, with a volume of 64390 shares traded. The stock had previously closed at $14.79.

Wall Street Analyst Weigh In

ANGO has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Zacks Research lowered AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. HC Wainwright raised their price target on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Finally, Canaccord Genuity Group lifted their price target on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, AngioDynamics has an average rating of “Hold” and a consensus price target of $19.50.

AngioDynamics Stock Performance

The firm has a market cap of $627.80 million, a price-to-earnings ratio of -17.46 and a beta of 0.33. The firm’s 50 day moving average is $12.94 and its 200-day moving average is $11.58.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The firm had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts predict that AngioDynamics, Inc. will post -0.27 EPS for the current year.

Insider Activity at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president directly owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC raised its position in shares of AngioDynamics by 146.4% in the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 1,199 shares during the period. Kemnay Advisory Services Inc. bought a new stake in shares of AngioDynamics during the 4th quarter worth $27,000. State of Wyoming acquired a new position in AngioDynamics in the 2nd quarter valued at $31,000. Russell Investments Group Ltd. grew its stake in AngioDynamics by 329.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 3,213 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in AngioDynamics by 359.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 4,268 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.